Metastatic CancerPhase 3NCT00002622
Talc in Treating Patients With Malignant Pleural Effusion
A Phase 3 study testing talc in people with Metastatic Cancer, run by Alliance for Clinical Trials in Oncology at 241 sites in 2 countries.
Trial summary
RATIONALE: Talc may relieve malignant pleural effusion. It is not yet known whether wet talc is more effective than dry talc in treating patients with malignant pleural effusion. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Metastatic Cancer
- What is being tested?
- talc
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 501 participants
- Where
- 241 sitesin 2 countries
- Study dates
- Dec 1994to Jan 2006
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS: Unilateral malignant pleural effusion requiring sclerosis (as judged by the attending surgeon) At least 3 months since treatment of contralateral effusion No chylous effusion
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: More than 2 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Able to undergo thoracoscopy under general or local anesthesia (as determined by the attending surgeon) Not pregnant Tests and observations must be completed within 1 week prior to randomization (chest x-ray within 1 week prior to procedure)
PRIOR CONCURRENT THERAPY: No prior intrapleural therapy No systemic therapy within 2 weeks prior to randomization or 2 weeks post pleurodesis Biologic therapy: Not specified Chemotherapy: No new systemic chemotherapy for 2 weeks prior to and at least 2 weeks after pleurodesis Endocrine therapy: No new hormonal therapy for 2 weeks prior to and at least 2 weeks after pleurodesis No concurrent steroids used as antiemetics Radiotherapy: Prior radiotherapy allowed No radiotherapy to entire hemithorax Palliative irradiation of symptomatic bone lesions allowed on the affected side if field does not include a significant portion of pleura Surgery: See Disease Characteristics
Trial locations and contacts
241 sites in 2 countries.
241 sites in 2 countries
United States224 sites
Akron General Medical Center
Akron, Ohio, 44302
Akron City Hospital
Akron, Ohio, 44309
Cancer Center of Albany Medical Center
Albany, New York, 12208
Veterans Affairs Medical Center - Albany
Albany, New York, 12208
Saint Joseph Medical Center
Albuquerque, New Mexico, 87102
Providence Cancer Therapy Center
Anchorage, Alaska, 99508
St. John's Medical Center
Anderson, Indiana, 46016
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
Anne Arundel Oncology Center
Annapolis, Maryland, 21401
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, 21201
Greater Baltimore Medical Center and Cancer Center
Baltimore, Maryland, 21204
Harbor Hospital Center
Baltimore, Maryland, 21225
Radiation Oncology Affiliates of Maryland, P.A.
Baltimore, Maryland, 21237
Johns Hopkins Oncology Center
Baltimore, Maryland, 21287
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Julie and Ben Rogers Cancer Institute
Beaumont, Texas, 77701
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Veterans Affairs Medical Center - Birmingham
Birmingham, Alabama, 35233
University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, 35294
Quain & Ramstad Clinic, P.C.
Bismarck, North Dakota, 58501
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Joint Center for Radiation Therapy
Boston, Massachusetts, 02215
Medical Center at Bowling Green
Bowling Green, Kentucky, 42102
Bridgeport Hospital
Bridgeport, Connecticut, 06610
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
New York Methodist Hospital
Brooklyn, New York, 11215-3609
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Providence Saint Joseph Medical Center - Burbank
Burbank, California, 91505
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
Martha Jefferson Hospital
Charlottesville, Virginia, 22901
Cancer Center, University of Virginia HSC
Charlottesville, Virginia, 22908
Northwestern Memorial Hospital
Chicago, Illinois, 60611
University of Chicago Cancer Research Center
Chicago, Illinois, 60637
Christ Hospital
Cincinnati, Ohio, 45219
Lykes Center for Radiation Therapy
Clearwater, Florida, 33757-0210
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
Memorial Hospital Cancer Center
Colorado Springs, Colorado, 80909
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
CCOP - Columbus
Columbus, Ohio, 43206
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210
Mount Diablo Medical Center
Concord, California, 94524-4110
Samaritan Regional Cancer Center
Corvallis, Oregon, 97339
Penn State Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Mercy Catholic Medical Center, Mercy Fitzgerald Divison
Darby, Pennsylvania, 19023
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
Halifax Medical Center
Daytona Beach, Florida, 32114
University of Colorado Cancer Center
Denver, Colorado, 80262
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 10309-1016
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
Beckman Research Institute, City of Hope
Duarte, California, 91010
Wendt Regional Cancer Center of Finley Hospital
Dubuque, Iowa, 52001
CCOP - Duluth
Duluth, Minnesota, 55805
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07018-1095
John F. Kennedy Medical Center
Edison, New Jersey, 08818
Elizabeth General Medical Center - West
Elizabeth, New Jersey, 07201
Meritcare Roger Maris Cancer Center
Fargo, North Dakota, 58122
Hurley Medical Center
Flint, Michigan, 48503
Radiation Therapy Associates - Fort Myers
Fort Myers, Florida, 33901
California Cancer Center
Fresno, California, 93720
Saint Agnes Cancer Center
Fresno, California, 93720
University of Florida Health Science Center
Gainesville, Florida, 32610-0296
University of Texas Medical Branch
Galveston, Texas, 77555-1329
Glendale Memorial Hospital and Health Center
Glendale, California, 91204
St. Vincent Hospital
Green Bay, Wisconsin, 54307-3508
Sutter Health Western Division Cancer Research Group
Greenbrae, California, 94904
East Carolina University School of Medicine
Greenville, North Carolina, 27858-4354
CCOP - Greenville
Greenville, South Carolina, 29615
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Penn State Geisinger Cancer Center
Hershey, Pennsylvania, 17033
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030
Huntsville Hospital System
Huntsville, Alabama, 35801
Cape Cod Hospital
Hyannis, Massachusetts, 02601
Clarion Health Partners Inc.
Indianapolis, Indiana, 46206-1367
Community Hospitals of Indianapolis - Regional Cancer Center
Indianapolis, Indiana, 46219
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
Jackson-Madison County General Hospital
Jackson, Tennessee, 38301
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
CCOP - Kansas City
Kansas City, Missouri, 64131
CCOP - Dayton
Kettering, Ohio, 45429
Baptist Regional Cancer Center - Knoxville
Knoxville, Tennessee, 37901
Gundersen Lutheran Medical Foundation
La Crosse, Wisconsin, 54601
Wilford Hall - 59th Medical Wing
Lackland Air Force Base, Texas, 78236-5300
Romagosa Radiation Oncology Center
Lafayette, Louisiana, 70501
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40511-1093
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
Loma Linda University Medical Center
Loma Linda, California, 92354
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
Kaiser Permanente Medical Center - Los Angeles
Los Angeles, California, 90027
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033-0800
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
James Graham Brown Cancer Center
Louisville, Kentucky, 40202
Louisville Radiation Oncology
Louisville, Kentucky, 40215
Virginia Baptist Hospital
Lynchburg, Virginia, 24503
Veterans Affairs Medical Center - Madison
Madison, Wisconsin, 53705
Southern Wisconsin Radiotherapy Center
Madison, Wisconsin, 53713
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
Merle M. Mahr Cancer Center
Madisonville, Kentucky, 42431
Elliot Regional Cancer Center
Manchester, New Hampshire, 03103
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Marquette General Hospital
Marquette, Michigan, 49855
Marshfield Clinic
Marshfield, Wisconsin, 54449
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
Loyola University Medical Center
Maywood, Illinois, 60153
Health First Holmes Regional Medical Center
Melbourne, Florida, 32901
CCOP - Baptist Cancer Institute
Memphis, Tennessee, 38117
University of Tennessee, Memphis Cancer Center
Memphis, Tennessee, 38163
Community Memorial Hospital
Menomonee Falls, Wisconsin, 53051
East Jefferson General Hospital
Metairie, Louisiana, 70011
Sylvester Cancer Center, University of Miami
Miami, Florida, 33136
Baptist Hospital of Miami
Miami, Florida, 33176-2197
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
South Jersey Hospital - Millville
Millville, New Jersey, 08332
St. Joseph's Hospital
Milwaukee, Wisconsin, 53210
Columbia Hospital
Milwaukee, Wisconsin, 53211
St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, 53295
UNI-MED Medical Center
Minot, North Dakota, 58701
Urology Associates - Mobile AL
Mobile, Alabama, 36640
MBCCOP - University of South Alabama
Mobile, Alabama, 36688
Alabama Oncology, LLC
Montgomery, Alabama, 36106-2801
Fox Chase Cancer Center at Virtua-Memorial Hospital Burlington County
Mount Holly, New Jersey, 08060
Ball Memorial Hospital
Muncie, Indiana, 47303-3499
Vanderbilt Cancer Center
Nashville, Tennessee, 37232-6838
MBCCOP - LSU Medical Center
New Orleans, Louisiana, 70112
CCOP - Ochsner
New Orleans, Louisiana, 70121
Kaplan Cancer Center
New York, New York, 10016
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021
Whittingham Cancer Center
Norwalk, Connecticut, 06856
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
Methodist Cancer Center - Omaha
Omaha, Nebraska, 68114
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68131
Florida Radiation Oncology Group
Orange Park, Florida, 32073
MD Anderson Cancer Center Orlando
Orlando, Florida, 32806
Western Baptist Hospital
Paducah, Kentucky, 42001
Gulf Coast Cancer Treatment Center
Panama City, Florida, 32405-4587
Lutheran General Cancer Care Center
Park Ridge, Illinois, 60068
Bayshore Medical Center
Pasadena, Texas, 77504
West Florida Cancer Institute - Pensacola
Pensacola, Florida, 32514
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Allegheny University Hospitals- Hahnemann
Philadelphia, Pennsylvania, 19102-1192
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104
Veterans Affairs Medical Center - Philadelphia
Philadelphia, Pennsylvania, 19104
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, 19141
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224
Champlain Valley Physicians Hospital Medical Center
Plattsburgh, New York, 12901
Cancer Care Center
Pomona, California, 91767
Maine Medical Center
Portland, Maine, 04102
CCOP - Columbia River Program
Portland, Oregon, 97213
Naval Medical Center, Portsmouth
Portsmouth, Virginia, 23708-2197
Vassar Brothers Hospital
Poughkeepsie, New York, 12601
Southeastern Wisconsin Regional Cancer Center
Racine, Wisconsin, 53405
Rapid City Regional Hospital
Rapid City, South Dakota, 57709
Reading Hospital and Medical Center
Reading, Pennsylvania, 19612-6052
Mercy Medical Center - Redding
Redding, California, 96099-6009
Massey Cancer Center
Richmond, Virginia, 23298-0037
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Genesee Hospital - Rochester
Rochester, New York, 14607
University of Rochester Cancer Center
Rochester, New York, 14642
InterCommunity Cancer Center at Rome
Rome, Georgia, 30161
Green Mountain Oncology Group
Rutland, Vermont, 05701
Radiation Oncology Center - Sacramento
Sacramento, California, 95816
St. Mary's Medical Center
Saginaw, Michigan, 48601
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
LDS Hospital
Salt Lake City, Utah, 84143
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94115-0128
Santa Cruz Radiation Oncology Medical Group, Inc.
Santa Cruz, California, 95065
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
CCOP - Scottsdale Oncology Program
Scottsdale, Arizona, 85259-5404
Mercy Hospital Cancer Center - Scranton
Scranton, Pennsylvania, 18501
Swedish Hospital Tumor Institute
Seattle, Washington, 98104
Virginia Mason Medical Center
Seattle, Washington, 98111
Grand View Hospital
Sellersville, Pennsylvania, 18960
Siouxland Hematology-Oncology
Sioux City, Iowa, 51101-1733
Memorial Hospital of South Bend
South Bend, Indiana, 46601
St. Joseph's Radiation Oncology Center
South Bend, Indiana, 46617
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Deaconess Medical Center
Spokane, Washington, 99210-0248
CCOP - Central Illinois
Springfield, Illinois, 62526
Cancer Research for the Ozarks
Springfield, Missouri, 65807
Veterans Affairs Medical Center - Saint Louis
St Louis, Missouri, 63106
St. Louis University Health Sciences Center
St Louis, Missouri, 63110-0250
Mallinckrodt Institute of Radiology
St Louis, Missouri, 63110
Dixie Regional Medical Center
St. George, Utah, 84770
Bayfront Medical Center
St. Petersburg, Florida, 33701
Stanford University
Stanford, California, 94305
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612
Albert Einstein Comprehensive Cancer Center
The Bronx, New York, 10461
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio, 43623-3456
Community Medical Center
Toms River, New Jersey, 08755
David Grant Medical Center
Travis Air Force Base, California, 94535
St. Francis Medical Center
Trenton, New Jersey, 08629
Arizona Cancer Center
Tucson, Arizona, 85724
St. John Medical Center
Tulsa, Oklahoma, 74104
Radiation Oncology Associates of West Alabama
Tuscallosa, Alabama, 35401
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
South Georgia Medical Center
Valdosta, Georgia, 31603
New York Medical College
Valhalla, New York, 10595
Radiation Oncology Center - Walnut Creek
Walnut Creek, California, 94598
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
Schiffler Oncology Center
Wheeling, West Virginia, 26003
Veterans Affairs Medical Center - White River Junction
White River Junction, Vermont, 05009
CCOP - Wichita
Wichita, Kansas, 67214-3882
Wilkes Barre General Hospital
Wilkes-Barre, Pennsylvania, 18764
CCOP - Christiana Care Health Services
Wilmington, Delaware, 19899
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina, 27104-4241
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, 27157-1082
CCOP - MainLine Health
Wynnewood, Pennsylvania, 19096
Yakima Valley Memorial Hospital
Yakima, Washington, 98902
York Hospital
York, Pennsylvania, 17315
Canada17 sites
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Northeastern Ontario Regional Cancer Centre, Sudbury
Greater Sudbury, Ontario, P3E 5J1
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7
Cancer Care Ontario-Hamilton Regional Cancer Centre
Hamilton, Ontario, L8V 5C2
Kingston Regional Cancer Centre
Kingston, Ontario, K7L 5P9
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6
Doctor Leon Richard Oncology Centre
Moncton, New Brunswick, E1C 8X3
McGill University Department of Oncology
Montreal, Quebec, H2W 1S6
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2W-W1T8
Ottawa Regional Cancer Centre - Civic Campus
Ottawa, Ontario, K1Y 4K7
Saskatchewan Cancer Agency
Regina, Saskatchewan, S4S 6X3
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Northwestern Ontario Regional Cancer Centre, Thunder Bay
Thunder Bay, Ontario, P7A 7T1
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
British Columbia Cancer Agency - Vancouver Island Cancer Centre
Victoria, British Columbia, V8R 1J8
About this study
Official title: Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
RATIONALE: Talc may relieve malignant pleural effusion. It is not yet known whether wet talc is more effective than dry talc in treating patients with malignant pleural effusion.
PURPOSE: Randomized phase III trial to compare the effectiveness of wet talc with dry talc in treating patients with malignant pleural effusion.
Read the detailed description
OBJECTIVES: I. Compare the proportion of patients with successful pleurodesis at 30 days following treatment for malignant pleural effusion (MPE) by talc slurry via chest tube vs thoracoscopic talc insufflation. II. Compare the cost and cost effectiveness of both treatments for MPE. III. Compare the time to recurrence of effusion, duration of chest tube drainage after sclerosis, extent of postinstillation complications and toxicities, and the ability to re-expand the lung in patients randomized to these 2 treatments. IV. Evaluate the quality of life and pain experienced by patients during both treatments.
OUTLINE: This is a randomized study. Patients are stratified according to participating institution. Patients are randomized to one of two treatment arms. Arm I: Patients undergo pleurodesis. A chest tube is inserted, the pleural fluid is drained for 24 hours, and the lung is re-expanded to at least 90% of full expansion. Within 24-36 hours patients undergo sclerosis with talc slurry injected into the chest tube, which is then clamped. Patients are rotated in all possible directions, holding each position for about 30 minutes. After 2 hours the chest tube is unclamped and reattached to suction drainage, which is strictly measured for 24-hour totals. Following a decrease in drainage to no more than 150 ml/24 hours (usually by the second or third day postsclerosis), the chest tube is removed. Arm II: Patients receive thoracoscopic insufflation. The chest is explored thoracoscopically via single or multiple incisions using direct or videothoracoscopic visualization, and the lung is re-expanded to 90% of full expansion. Dry talc is pneumatically insufflated into the chest, with complete dispersion throughout the hemithorax. Following insufflation, the chest is drained via a chest tube, which is removed when the drainage is no more than 150 ml/24 hours (usually by day 2 or 3 following insufflation). Patients are removed from study for disease progression or an unsuccessful lung re-expansion. Patients are followed monthly for 6 months for relapse and survival.
PROJECTED ACCRUAL: Approximately 500 patients will be accrued for this study over 28 months.
- Conditions
- Metastatic Cancer
- Being tested
- talc
- Keywords
- malignant pleural effusion
- Medical subject headings
- Neoplasm Metastasis, Pleural Effusion, Malignant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
talcDrug
4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
TalcDrug
4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
| Study group | Role | What they receive |
|---|---|---|
| Talc slurry via chest tube | Active comparator | talc slurry via chest tube Receives: Drug: talc |
| Talc via insufflation | Active comparator | 4 to 5 grams talc via insufflation through direct or videoscopic thoracoscopy, one time Receives: Drug: Talc |
What is being measured
The primary outcome is the main question the study is designed to answer.
Successful pleurodesis
Measured: 30 days
Cost and cost effectiveness
cost and cost effectiveness of treating malignant pleural effusions
Measured: 30 days
Secondary outcomes (2)
Time to recurrence of effusion
Measured: 6 months
Complications and toxicity
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2004 (estimated)
- Study startDec 1994
- Primary completionMar 2005
- Study completionJan 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Metastatic CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 501 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), Eastern Cooperative Oncology Group, Radiation Therapy Oncology Group, North Central Cancer Treatment Group
- Responsible party
- Sponsor
- Investigators
- Jemi Olak, MD, Study chair, Kern Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00002622
- Sponsor's protocol ID
- CALGB-9334
- Other IDs
- U10CA031946, CLB-9334, E-C9334, NCCTG-C9334, RTOG-9511, CDR0000063982
- Status last verified
- Jun 2016
- First submitted
- 1 Nov 1999
- Last updated
- 28 Jun 2016
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, Daniel TM, Haasler GB, Sugarbaker DJ; Cooperative Groups Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cooperative Oncology Group; Radiation Therapy Oncology Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005 Mar;127(3):909-15. doi: 10.1378/chest.127.3.909.
PubMed 15764775Fleishman SB, Dresler C, Herndon JE, et al.: Quality of life (QOL) advantage of sclerosis for malignant pleural effusion (MPE) via talc thoracoscopy over chest tube infusion of talc slurry: a cancer and leukemia group B study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1418, 2002.
Dresler CM, Herndon JE, Daniels T, et al.: Cancer and Leukemia Group B (CALGB) 9334: a phase III, intergroup study of sclerosis of malignant pleural effusion by talc. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A2455, 2000.
Study at a glance
From the registry record, last updated by the sponsor on 28 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
- ClinicalTrials.gov ID
- NCT00002622
- Acronym / sponsor ID
- CALGB-9334
- Conditions
- Metastatic Cancer
- Keywords
- malignant pleural effusion
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 501 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), Eastern Cooperative Oncology Group, Radiation Therapy Oncology Group, North Central Cancer Treatment Group
- Study start
- Dec 1994
- Primary completion
- Mar 2005 (actual)
- Study completion
- Jan 2006 (actual)
- First posted
- 31 Aug 2004 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Talc may relieve malignant pleural effusion. It is not yet known whether wet talc is more effective than dry talc in treating patients with malignant pleural effusion.
PURPOSE: Randomized phase III trial to compare the effectiveness of wet talc with dry talc in treating patients with malignant pleural effusion.
Detailed description
OBJECTIVES: I. Compare the proportion of patients with successful pleurodesis at 30 days following treatment for malignant pleural effusion (MPE) by talc slurry via chest tube vs thoracoscopic talc insufflation. II. Compare the cost and cost effectiveness of both treatments for MPE. III. Compare the time to recurrence of effusion, duration of chest tube drainage after sclerosis, extent of postinstillation complications and toxicities, and the ability to re-expand the lung in patients randomized to these 2 treatments. IV. Evaluate the quality of life and pain experienced by patients during both treatments.
OUTLINE: This is a randomized study. Patients are stratified according to participating institution. Patients are randomized to one of two treatment arms. Arm I: Patients undergo pleurodesis. A chest tube is inserted, the pleural fluid is drained for 24 hours, and the lung is re-expanded to at least 90% of full expansion. Within 24-36 hours patients undergo sclerosis with talc slurry injected into the chest tube, which is then clamped. Patients are rotated in all possible directions, holding each position for about 30 minutes. After 2 hours the chest tube is unclamped and reattached to suction drainage, which is strictly measured for 24-hour totals. Following a decrease in drainage to no more than 150 ml/24 hours (usually by the second or third day postsclerosis), the chest tube is removed. Arm II: Patients receive thoracoscopic insufflation. The chest is explored thoracoscopically via single or multiple incisions using direct or videothoracoscopic visualization, and the lung is re-expanded to 90% of full expansion. Dry talc is pneumatically insufflated into the chest, with complete dispersion throughout the hemithorax. Following insufflation, the chest is drained via a chest tube, which is removed when the drainage is no more than 150 ml/24 hours (usually by day 2 or 3 following insufflation). Patients are removed from study for disease progression or an unsuccessful lung re-expansion. Patients are followed monthly for 6 months for relapse and survival.
PROJECTED ACCRUAL: Approximately 500 patients will be accrued for this study over 28 months.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Talc slurry via chest tube | Active comparator | Drug: talctalc slurry via chest tube |
| Talc via insufflation | Active comparator | Drug: Talc4 to 5 grams talc via insufflation through direct or videoscopic thoracoscopy, one time |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| talc4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time | Drug | Talc slurry via chest tube |
| Talc4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time | Drug | Talc via insufflation |
Primary outcome
Successful pleurodesis
Time frame: 30 days
Cost and cost effectiveness
Time frame: 30 days
cost and cost effectiveness of treating malignant pleural effusions
2 secondary outcomes
Time to recurrence of effusion
Time frame: 6 months
Complications and toxicity
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jun 2016.
- Results publication: PubMed 15764775Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, Daniel TM, Haasler GB, Sugarbaker DJ; Cooperative Groups Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cooperative Oncology Group; Radiation Therapy Oncology Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005 Mar;127(3):909-15. doi: 10.1378/chest.127.3.909.
- Results publicationFleishman SB, Dresler C, Herndon JE, et al.: Quality of life (QOL) advantage of sclerosis for malignant pleural effusion (MPE) via talc thoracoscopy over chest tube infusion of talc slurry: a cancer and leukemia group B study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1418, 2002.
- Results publicationDresler CM, Herndon JE, Daniels T, et al.: Cancer and Leukemia Group B (CALGB) 9334: a phase III, intergroup study of sclerosis of malignant pleural effusion by talc. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A2455, 2000.
Related trials for Metastatic Cancer
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Not yet recruitingPhase 1
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
Advanced or Metastatic Breast Cancer
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
RecruitingPhase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
RecruitingPhase 2
Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma
Soft Tissue Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jemi Olak, MD study chair
Kern Medical Center
241 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing talc in people with Metastatic Cancer, run by Alliance for Clinical Trials in Oncology at 241 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 241 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Successful pleurodesis (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00002622, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jun 2016.